Terug naar bedrijfspagina

Nieuws over argenx

20/11/2024 argenx - Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies (20.11.2024)

27/12/2022 Argenx: "We moeten biotech blijven en geen farma"

27/10/2022 Argenx stookt Vyvgart locomotief sneller op

22/10/2020 argenx - Reports Third Quarter 2020 Financial Results and Provides Business Update (22.10.2020)

30/07/2020 argenx - reports half year 2020 financial results and provides second quarter business update (30.7.2020)

28/05/2020 Argenx (KBC)

27/05/2020 argenx Announces Positive Topline Phase 3 ADAPT Trial Results (26.5.2020)

05/02/2020 Opiniewijzigingen voor argenx, Apple, LVMH, Nintendo, Stryker en CFE (The Markets! Dierickx Leys Private Bank)

26/06/2019 Beleggen in biotech is 'risky business' (Test-Aankoop invest)

28/05/2019 argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology (28.5.2019)

22/05/2019 argenx - pipeline expansion and vision to build integrated immunology company at 2019 R&D Day(22.5.2019)

15/05/2019 Argenx - to Host R&D Day on May 22, 2019 (15.5.2019)

08/05/2019 argenx - to Present at Bank of America Merrill Lynch 2019 Health Care Conference (8.5.2019)

20/03/2019 argenx (KBC)

14/03/2019 Argenx to receive first clinical milestone payment for product candidate developed (14/03/19)

28/02/2019 argenx reports fourth quarter business update and full year results (28.2.2019)

21/02/2019 argenx to host conference call feb 28 (21.2.2019)

12/12/2018 argenx blijft hoge verwachtingen inlossen (Inside Beleggen - Trends)

03/12/2018 Argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)

03/12/2018 Argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia (3.12.2018)

08/11/2018 2018 08 - Interview met Tim van Hauwermeiren, ceo argenx

25/10/2018 argenx reports third quarter 2018 financial results and provides business update (25.10.2018)

09/10/2018 argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology (9.10.2018)

26/09/2018 argenx: Hoger koersdoel (KBC)

19/09/2018 argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering (19.9.2018)

18/09/2018 argenx announces launch of proposed public offering in the United States (18.9.2018)

17/09/2018 argenx scoort met ARGX-113 onderzoek (KBC)

17/09/2018 argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia (17.9.2018)

06/09/2018 argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis (6.9.2018)

29/08/2018 argenx receives feedback from Japan’s PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis (29.8.2018)

22/08/2018 Argenx- AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody (22.8.2018)

09/05/2018 Kwartaalupdates Ontex, Kinepolis en argenx (KBC)

08/05/2018 2018 05 - Klaar voor de volgende stap

13/12/2017 argenx (KBC)

30/12/2016 2017 01 - Bedrijfsbezoek argenx

27/05/2015 Bolero: aandeel in de kijker is arGEN-X

20/05/2015 Bolero: aandeel in de kijker is Argen-X

02/03/2015 2015 03 - Interview met ceo Tim Van Hauwermeiren

27/08/2014 2014 07 - De nieuwe parels aan de kroon?